Shijiazhuang Yiling Pharmaceutical (002603.SZ) Obtains Approval for Memantine Hydrochloride API Marketing Application

Stock News11-12

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. ("Hengshui Wanyang"), recently received the "Chemical Drug API Marketing Approval Notice" from the National Medical Products Administration (NMPA). The marketing application for Memantine Hydrochloride API submitted by Hengshui Wanyang has been approved.

Memantine Hydrochloride is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist. It blocks neuronal damage caused by pathological elevation of glutamate concentrations and is used to treat moderate to severe Alzheimer's-type dementia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126379899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126379899","market":"sh","top_or_hot":-1,"title":"Shijiazhuang Yiling Pharmaceutical (002603.SZ) Obtains Approval for Memantine Hydrochloride API Marketing Application","media":"Stock News","content":"<p>Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (\"Hengshui Wanyang\"), recently received the \"Chemical Drug API Marketing Approval Notice\" from the National Medical Products Administration (NMPA). The marketing application for Memantine Hydrochloride API submitted by Hengshui Wanyang has been approved.</p>\n<p>Memantine Hydrochloride is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist. It blocks neuronal damage caused by pathological elevation of glutamate concentrations and is used to treat moderate to severe Alzheimer's-type dementia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shijiazhuang Yiling Pharmaceutical (002603.SZ) Obtains Approval for Memantine Hydrochloride API Marketing Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShijiazhuang Yiling Pharmaceutical (002603.SZ) Obtains Approval for Memantine Hydrochloride API Marketing Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-12 16:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (\"Hengshui Wanyang\"), recently received the \"Chemical Drug API Marketing Approval Notice\" from the National Medical Products Administration (NMPA). The marketing application for Memantine Hydrochloride API submitted by Hengshui Wanyang has been approved.</p>\n<p>Memantine Hydrochloride is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist. It blocks neuronal damage caused by pathological elevation of glutamate concentrations and is used to treat moderate to severe Alzheimer's-type dementia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1126379899","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126379899","pubTimestamp":1762936105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (\"Hengshui Wanyang\"), recently received the \"Chemical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0046":"生物疫苗","002603":"以岭药业","BK0042":"基因检测","BK0097":"医药电商","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"石家庄以岭药业（002603.SZ）盐酸美金刚原料药上市申请获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002603":1},"content_text":"Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (\"Hengshui Wanyang\"), recently received the \"Chemical Drug API Marketing Approval Notice\" from the National Medical Products Administration (NMPA). The marketing application for Memantine Hydrochloride API submitted by Hengshui Wanyang has been approved.\nMemantine Hydrochloride is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist. It blocks neuronal damage caused by pathological elevation of glutamate concentrations and is used to treat moderate to severe Alzheimer's-type dementia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126379899","isCrawlerRequest":true}